PV Bulletin
PvBulletin
Home /Latest/MaaT Pharma flags CHMP “negative trend” ahead of June vote
LatestEma

MaaT Pharma flags CHMP “negative trend” ahead of June vote

MaaT Pharma said an EMA CHMP oral explanation resulted in a “negative trend” ahead of a June vote on the MaaT013 (Xervyteg) EU marketing authorization application, with re-examination planned if the formal vote is negative.

PV Impact Brief

Urgency: MediumConfidence: medium
Relevant for
Signal Management LeadLabeling LeadRegulatory Intelligence LeadPV Technology / CSV LeadAggregate Reports LeadQPPV
Processes impacted
Label GovernanceRisk ManagementAI / GxP GovernanceAggregate ReportingRegulatory Intelligence Monitoring
Action needed

Ema update requires triage for Label Governance, Risk Management, AI / GxP Governance; confirm local obligations and document follow-up actions.

Owner

Signal Management Lead

Review cadence

Review in the next governance cycle and track weekly until closure.

Evidence and confidence

Confidence: mediumSource updated: May 21, 2026

Primary-source confirmation recommended before operational implementation.

Full briefing

What changed

MaaT Pharma said an EMA CHMP oral explanation resulted in a “negative trend” ahead of a June vote on the MaaT013 (Xervyteg) EU marketing authorization application, with re-examination planned if the formal vote is negative.

Why it matters

Potential impact spans Label Governance, Risk Management, AI / GxP Governance, Aggregate Reporting, Regulatory Intelligence Monitoring, so Signal Management Lead oversight is needed to maintain compliance readiness and evidence traceability.

Practical implication

Ema update requires triage for Label Governance, Risk Management, AI / GxP Governance; confirm local obligations and document follow-up actions.

#Risk Management#Labeling#Aggregate Reporting#Breaking News#EMA#Benefit Risk

Related updates for your role

RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUnited States

FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients

Regulatory action
Public Notification
Tawon Liar
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUSA

Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)

Regulatory action
Class 2 Device Recall
PhaseOne Antimicrobial Solution · Oculus Technologies of Mexico, S.A. de C.V.
Lot/batch: 25G263
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief →
MaaT Pharma flags CHMP “negative trend” ahead of June vote | PV Bulletin